AOD 9604 Injection: What It Is, How It Is Used, and Safety

AOD 9604 injection is a subcutaneous shot of a synthetic peptide fragment of human growth hormone, promoted for fat loss and body recomposition. AOD 9604 is not FDA-approved for human use in the United States, so every vial sold for injection is technically a research chemical rather than a regulated medication. Human safety and efficacy data are limited, and anyone considering it should speak with a licensed healthcare professional first.

What Is AOD 9604?

AOD 9604 is a short synthetic fragment of human growth hormone that corresponds to the region spanning amino acids 176 through 191. Scientists isolated that piece of the HGH molecule because it appeared to act on fat cells without triggering the growth-promoting effects of the full hormone.

AOD 9604 does not meaningfully raise IGF-1 levels the way recombinant HGH does, and it does not appear to affect blood sugar the same way. That profile is why it is often grouped with fat-loss peptides in research and fitness communities.

The peptide ships as a freeze-dried powder that must be reconstituted before use. Most vendors label it for research use only, which signals that it has not been reviewed by the FDA for human injection.

How AOD 9604 Injection Is Used

Standard protocols describe subcutaneous injection: a shallow shot into the fat layer of the abdomen, thigh, or upper arm using a 29- to 31-gauge insulin syringe. The powder is dissolved in bacteriostatic water, and the mixed solution is kept refrigerated and away from light.

Reconstitution basics

Reconstitution is simply the step where peptide powder is mixed with sterile water. The volume of water you add determines how many micrograms sit in each unit on the syringe, so the math has to be right before the first injection.

Vial Size	Water Added	Concentration	Volume for 300 mcg
2 mg	2 mL	1 mg/mL	0.30 mL (30 units)
5 mg	2 mL	2.5 mg/mL	0.12 mL (12 units)
5 mg	5 mL	1 mg/mL	0.30 mL (30 units)
10 mg	5 mL	2 mg/mL	0.15 mL (15 units)

Common mistakes during aod 9604 reconstitution include spraying water directly onto the powder, shaking the vial to speed things up, and reusing needles between draws. A slow swirl and a gentle roll is enough to dissolve the peptide without damaging it.

Dosage and timing

Most protocols published online fall between 250 mcg and 500 mcg once per day, and 300 mcg is the most frequently cited amount. Typical timing is in the morning on an empty stomach, sometimes before fasted cardio.

Every discussion of aod 9604 dosage is based on user reports and small studies rather than an approved product label. There is no officially recognized dose, and taking more does not reliably produce better results.

Injection vs. Nasal Spray vs. Oral

Delivery route determines how much of the peptide actually reaches circulation. That is the heart of the aod 9604 nasal spray vs injection question: injections deliver a measured dose under the skin, while sprays depend on absorption through nasal tissue.

Route	Absorption	Common Use	Main Drawback
Subcutaneous injection	High and consistent	Most research and user protocols	Requires sterile technique
Nasal spray	Lower and variable	Convenience-focused users	Limited uptake through the nasal lining
Oral capsule	Poor	Sold as a supplement	Broken down by digestion

Injectable products carry infection risk whenever sterility is compromised, and nasal sprays can irritate the nasal lining with repeated use. Oral capsules are the least predictable route because stomach acid and digestive enzymes degrade peptides before they reach the bloodstream.

AOD 9604 vs. Tesamorelin

These two peptides are often compared because both are linked to fat reduction, but they work through completely different mechanisms. The clearest dividing line in any aod 9604 vs tesamorelin comparison is regulatory status.

Feature	AOD 9604	Tesamorelin
Structure	Fragment of HGH (amino acids 176-191)	Growth hormone-releasing hormone analog
FDA approval	Not approved for human use	Approved for HIV-associated lipodystrophy
Mechanism	Acts on fat cells directly	Stimulates pituitary growth hormone release
IGF-1 effect	Minimal	Raises IGF-1
Typical dose	250-500 mcg per day	1-2 mg per day

Tesamorelin raises endogenous growth hormone and IGF-1, which brings growth-hormone-related risks such as fluid retention, joint pain, and elevated blood sugar. AOD 9604 appears to leave IGF-1 alone, but that same selectivity may limit how much it can accomplish.

Benefits, Side Effects, and What the Evidence Shows

Reported aod 9604 benefits and side effects come mostly from user anecdotes and small trials, not from large randomized studies. Enthusiasts describe reduced body fat, preserved lean mass, and no change in blood glucose, but the supporting evidence remains thin.

Commonly reported side effects

• Redness, bruising, or soreness at the injection site
• Headache, nausea, or fatigue shortly after dosing
• Water retention or mild joint discomfort
• Unknown long-term risks, including immune reactions to a foreign peptide

What the research actually shows

Early Australian trials of AOD9604 in adults with obesity reported modest fat loss, but later studies produced weaker results and regulators declined to approve the drug. No large, long-term safety trial in humans has been completed.

Online reviews are useful for spotting patterns but not for medical decisions, because they are self-reported, unverified, and frequently written by people using several other compounds at the same time.

Safety, Legality, and Sourcing Risks

Because AOD 9604 is sold as a research chemical, it is not held to pharmaceutical manufacturing standards. Independent testing has repeatedly found mislabeled peptides, incorrect concentrations, and bacterial contamination in gray-market vials.

There is no regulated supply chain, no guaranteed purity, and no recourse if a product causes harm. Sterile technique and proper needle disposal matter more than any dose chart.

Anyone who is pregnant, breastfeeding, or living with cancer, diabetes, or a hormone-sensitive condition should avoid unapproved peptides unless a physician specifically recommends them.

Bottom Line

AOD 9604 injection is an experimental growth hormone fragment that is marketed for fat loss but is not FDA-approved for human use. The human evidence is limited and inconsistent, and the best-documented dangers come from unsterile or mislabeled products rather than the peptide itself.

For fat loss, approaches with real safety data, including nutrition, resistance training, sleep, and prescription treatments supervised by a doctor, have a far stronger track record. Talk with a licensed healthcare provider before injecting any research chemical.

COMMON QUESTIONS

Frequently Asked Questions

Is AOD 9604 injection FDA-approved?

No. AOD 9604 is not FDA-approved for any human use in the United States. It is sold as a research chemical, which means it has not been reviewed for safety, purity, or effectiveness, and no approved version exists.

How much AOD 9604 do people inject per day?

Protocols shared online usually call for 250 to 500 micrograms once daily, with 300 micrograms being the most common figure. Injections are typically done subcutaneously in the morning on an empty stomach. Because the peptide is not approved, there is no officially recognized dosing schedule.

Does AOD 9604 injection help with weight loss?

Early small trials reported modest fat loss, but later studies showed weaker results and the drug was never approved. There is no large, long-term human trial confirming meaningful weight loss. Anyone seeking reliable fat loss should discuss proven options with a healthcare provider.